A phase II trial with monoclonal antibody CG250 in advanced renal cell carcinoma.

被引：0
|
作者：
Varga, Z
Hegele, A
Hofmann, R
De Mulder, PD
Kruit, W
Warnaar, S
Mala, C
Ullrich, S
Huber, C
Lamers, C
Beck, J
机构：
来源：
JOURNAL OF UROLOGY | 2002年 / 167卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：192 / 193
页数：2
相关论文
共 50 条
  • [21] Effect of tyrosine kinase inhibitor treatment of renal cell carcinoma on the accumulation of carbonic anhydrase IX-specific chimeric monoclonal antibody cG250
    Oosterwijk-Wakka, Jeannette C.
    Kats-Ugurlu, Gursah
    Leenders, William P. J.
    Kiemeney, Lambertus A. L. M.
    Old, Lloyd J.
    Mulders, Peter F. A.
    Oosterwijk, Egbert
    BJU INTERNATIONAL, 2011, 107 (01) : 118 - 125
  • [22] ImmunoPET imaging of renal cell carcinoma with 124I-and 89Zr-labeled anti-CAIX monoclonal antibody cG250
    Stillebroer, Alexander
    Franssen, Gerben
    Oyen, Wim
    Oosterwijk, Egbert
    Laverman, Peter
    Mulders, Peter
    Boerman, Otto
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51
  • [23] IMMUNOPET IMAGING OF RENAL CELL CARCINOMA WITH 124I-AND 89ZR-LABELED ANTI-CAIX MONOCLONAL ANTIBODY CG250
    Stillebroer, A.
    Franssen, G. M.
    Boerman, O. C.
    Oosterwijk, E.
    Laverman, P.
    Oyen, W. J. G.
    Mulders, P. F. A.
    EUROPEAN UROLOGY SUPPLEMENTS, 2010, 9 (02) : 153 - 154
  • [24] PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats
    Brouwers, A
    Verel, I
    Van Eerd, J
    Visser, G
    Steffens, M
    Oosterwijk, E
    Corstens, F
    Oyen, W
    Van Dongen, G
    Boerman, O
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2004, 19 (02) : 155 - 163
  • [25] ImmunoPET Imaging of Renal Cell Carcinoma with 124I- and 89Zr-Labeled Anti-CAIX Monoclonal Antibody cG250 in Mice
    Stillebroer, Alexander B.
    Franssen, Gerben M.
    Mulders, Peter F. A.
    Oyen, Wim J. G.
    van Dongen, Guus A. M. S.
    Laverman, Peter
    Oosterwijk, Egbert
    Boerman, Otto C.
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2013, 28 (07) : 510 - 515
  • [26] Traced labeled 131I chimeric clonal antibody (cG250) nv patients with renal cell carcinoma (RCC).
    Wiseman, GA
    Scott, AM
    Gansen, DN
    Lee, FT
    Hopkins, W
    Old, LJ
    Hoffman, EW
    Warnaar, S
    JOURNAL OF NUCLEAR MEDICINE, 2001, 42 (05) : 310P - 310P
  • [27] Higher uptake in renal cell carcinoma (RCC) metastases with 111In-labeled chimeric monoclonal antibody G250 (cG250) than with 131I-cG250 in an intra-patient comparison.
    Brouwers, AH
    Buijs, WC
    Boerman, OC
    Oosterwijk, E
    De Mulder, PH
    Corstens, FH
    Mulders, PF
    JOURNAL OF NUCLEAR MEDICINE, 2003, 44 (05) : 171P - 172P
  • [28] Combination of sunitinib and mAb cG250 in nude mice bearing human renal cell carcinoma xenografts
    Oosterwijk-Wakka, J. C.
    Mulders, P. F. A.
    Oosterwijk, E.
    EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E200 - E200
  • [29] Optimization of radioimmunotherapy of renal cell carcinoma:: Labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re
    Brouwers, AH
    van Eerd, JEM
    Frielink, C
    Oosterwijk, E
    Oyen, WJG
    Corstens, FHM
    Boerman, OC
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (02) : 327 - 337
  • [30] Update of survival data for two phase II studies with monoclonal antibody cG250 (rencarex®) in combination with IL-2 or IFN alpha-2a in metastatic renal cell cancer patients
    Neville, Norman G.
    Kloepfer, Pia
    Bevan, Paul
    Mala, Carola
    Beck, Joachim
    Hofmann, Rainer
    Kindler, Manfred
    Mulders, Peter F.
    Siebels, Michael
    Oberneder, R.
    JOURNAL OF UROLOGY, 2007, 177 (04): : 301 - 302
12345